Updated Jul 16, 2026
JEFFS ROGER has filed 11 SEC Form 4 filings across 2 companies in the last 90 days — selling. Lifetime open-market sales: $43.84M.
Roger Jeffs is a corporate executive known for his roles as Chief Executive Officer and Director at Liquidia Corp, a biopharmaceutical company focused on pulmonary hypertension treatments. He has also been involved with Axsome Therapeutics, Inc.
| Role | Chief Executive Officer, Director |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-15 | LQDA | Liquidia Corp | S — Open-market sale [10b5-1] | 32.7K | $71.52 | $2.34M |
| 2026-07-15 | LQDA | Liquidia Corp | S — Open-market sale [10b5-1] | 2.5K | $71.39 | $179K |
| 2026-07-15 | LQDA | Liquidia Corp | M — Option exercise [10b5-1] | 14.3K | — | |
| 2026-07-15 | LQDA | Liquidia Corp | M — Option exercise [10b5-1] | 13.8K | — | |
| 2026-06-12 | AXSM | Axsome Therapeutics, Inc. | S — Open-market sale | 286 | $249.12 | $71K |
| 2026-06-12 | AXSM | Axsome Therapeutics, Inc. | S — Open-market sale | 286 | $246.18 | $70K |
| 2026-06-11 | AXSM | Axsome Therapeutics, Inc. | M — Option exercise | 1.4K | — | |
| 2026-05-28 | LQDA | Liquidia Corp | S — Open-market sale | 6.4K | $62.18 | $400K |
| 2026-05-26 | LQDA | Liquidia Corp | S — Open-market sale | 25.0K | $60.38 | $1.51M |
| 2026-05-26 | LQDA | Liquidia Corp | S — Open-market sale | 25.0K | $61.52 | $1.54M |
| 2026-05-26 | LQDA | Liquidia Corp | S — Open-market sale | 25.0K | $61.13 | $1.53M |
| 2026-05-20 | LQDA | Liquidia Corp | S — Open-market sale | 25.0K | $61.30 | $1.53M |
| 2026-05-20 | LQDA | Liquidia Corp | S — Open-market sale | 25.0K | $58.65 | $1.47M |
| 2026-05-20 | LQDA | Liquidia Corp | S — Open-market sale | 25.0K | $56.77 | $1.42M |
| 2026-05-15 | LQDA | Liquidia Corp | S — Open-market sale | 25.0K | $57.04 | $1.43M |
| 2026-05-15 | LQDA | Liquidia Corp | S — Open-market sale | 25.0K | $58.62 | $1.47M |
| 2026-05-15 | LQDA | Liquidia Corp | S — Open-market sale | 25.0K | $56.29 | $1.41M |
| 2026-05-12 | LQDA | Liquidia Corp | S — Open-market sale | 25.0K | $54.04 | $1.35M |
| 2026-05-12 | LQDA | Liquidia Corp | S — Open-market sale | 25.0K | $41.50 | $1.04M |
| 2026-05-12 | LQDA | Liquidia Corp | S — Open-market sale | 25.0K | $42.14 | $1.05M |
Roger Jeffs is a corporate executive known for his roles as Chief Executive Officer and Director at Liquidia Corp, a biopharmaceutical company focused on pulmonary hypertension treatments. He has also been involved with Axsome Therapeutics, Inc.…
11 primary Form 4 filings in the last 90 days, covering 2 companies.
Recorded transactions: 0 open-market purchases () and 38 open-market sales ($43.84M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live JEFFS ROGER profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.